ePrescribing Market worth $3.3 billion by 2025 - Exclusive Report by MarketsandMarkets™

 According to the new market research report, "ePrescribing Market by Product & Services (Solution (Integrated, Standalone), Services(Implementation, Network)),by Delivery Mode (Web & Cloud based, On premise) End User (Hospitals, Physician Offices, Pharmacies), COVID-19 Impact-Global Forecast to 2025" The global ePrescribing market size is projected to reach USD 3.3 billion by 2025 from USD 1.2 billion in 2020, at a CAGR of 23.3%.

Browse and in-depth TOC on "ePrescribing Market"
150 - Tables
43 - Figures
196 - Pages

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=910

Global Industry Growth Boosting Factors:

Factors such as the increasing adoption of EHR solutions, government initiatives and incentive programs, rising focus on reducing the abuse of controlled substances, increasing focus on reducing medical errors, and the need to curtail the escalating healthcare costs are driving the growth of the e-prescribing market. Additionally, the onset of the COVID-19 pandemic has accelerated the use of telemedicine modules and telehealth consultations. This is further driving the adoption of e-prescribing solutions. However, the high cost of deploying e-prescribing solutions, reluctance among healthcare professionals to adopt these solutions, and concerns regarding security and workflow are expected to restrain the growth of this market to a certain extent during the forecast period.

The ePrescribing market is segmented based on the type of product & service, delivery mode, end user, and region. Due to lockdown restrictions and social distancing protocols due to COVID-19 across various countries through the first half of 2020, the market saw an increase in the number of telehealth consultations followed by use of eprescribing solutions to prescribe medicines.  Additionally, governments across countries are trying to regulate and expedite the use of ePrescribng functionality with telehealth functionality to avoid unnecessary hospital visits. Hence, the market is expected to show a slight increase in size due to increased adoption of these solutions.

The solutions accounted for the largest share of the ePrescribing market, by type of product & service, in 2019.

Based on product and service, the e-prescribing market is segmented into solutions and services. The solutions segment is further categorized as integrated and standalone solutions, and the services segment is categorized as network, support and maintenance, implementation, and training and education services. In 2019, the solutions segment accounted for the largest share of the e-prescribing market. The large share of the solutions segment can be attributed to the growing focus on minimizing the abuse of controlled substances, increasing adoption of e-prescribing, government initiatives and incentive programs to increase the adoption of e-prescribing solutions.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=910

Web and Cloud based solutions is the largest segment of the ePresciribng market, by delivery mode

Based on the mode of delivery, the e-prescribing market is segmented into on-premise and web- and cloudbased models. In 2019, the web- and cloud-based solutions segment accounted for the largest share of the global e-prescribing market. This segment is also projected to register the highest CAGR during the forecast period. The web- and cloud-based model offers improved performance and reliability by avoiding long deployment cycles. It also minimizes upfront investments without incurring high infrastructure costs as the user can access the software from any compatible system using an access ID or username and password. These advantages are supporting the growth of the web- and cloud-based solutions segment.

North America will continue to dominate the ePrescribing market in 2025

In 2019, the large share of this North American region can be attributed to the stringent legislative and accreditation requirements regarding healthcare, high adoption of HCIT technologies, regulatory requirements regarding patient safety, and the presence of a large number of e-prescribing solution providers in the region.

Key Players:

Prominent players in the global e-prescribing market are Epic Systems Corporation (US), Cerner Corporation (US), Allscripts (US), NextGen Healthcare (US), athenahealth, Inc. (US), RelayHealth, LLC (US), Henry Schein, Inc. (US), GE Healthcare (US), Computer Programs and Systems Inc. (US), DrFirst, Inc. (US), Surescripts-RxHub, LLC (US), and Medical Information Technology, Inc. (US).

Speak to Analyst@
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=910

Brain Monitoring Market - Future Revenue Growth Dynamics & Emerging Trends

 According to the new market research report, "Brain Monitoring Market by Product (Accessories, MRI, CT, PET, EEG, EMG, MEG, ICP, Electrode, Paste, Gel, Battery, Cable, Invasive), Disease (TBI, Stroke, Dementia, Epilepsy, Headache, Sleep) & End User (Hospital, Clinic, ASC) - Global Forecasts to 2026" The global brain monitoring market size is projected to reach USD 8.0 billion by 2026 from USD 5.8 billion in 2021, at a CAGR of 6.5%.

Browse and in-depth TOC on "Brain Monitoring Market"
312 - Tables
44 - Figures
267 - Pages

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=909

Global Industry Growth Boosting Factors:

The brain monitoring market is mainly driven by factors such as the increasing incidence and prevalence of neurological disorders, rising awareness of neurodegenerative diseases, growth in the number of traumatic brain injuries, and growing applications of brain monitoring in clinical trials. On the other hand, the high cost of complex brain monitoring procedures and devices, unfavorable reimbursement policies, and the shortage of trained professionals to effectively operate brain monitoring devices are restraining the growth of this market.

The companies have a large market spread across various countries in North America, Europe, Asia Pacific, and the Rest of the World.

Impact of covid-19 on The brain monitoring Market

The state of urgency to combat the outbreak has led to a significant increase in the demand for remote monitoring and patient engagement solutions. Most of the hospitals/healthcare facilities are currently trying to expand patient monitoring to home care settings or other temporary setups with an aim to provide optimal care. COVID-19 has led to a significant surge in demand for ventilators, and manufacturers are currently focusing their efforts to meet the increasing need for ventilators, including other respiratory devices, in contrast to brain monitoring devices. The pandemic is likely to have an adverse impact on the brain monitoring business, particularly due to the focus of hospitals on setting up COVID-19 specific ICUs, along with the temporary suspension of production and manufacturing sites in major affected regions across the globe.

The devices segment accounted for the largest share 74.9% of the brain monitoring market.

By product, the global brain monitoring market is categorized into devices and accessories. The devices segment held the largest share 74.9% of the brain monitoring market in 2020. This is mainly due to the rising incidence of neurological, neurodegenerative, psychotic, and sleep disorders, the need for early diagnosis, the availability of innovative portable and wearable home-based monitoring devices, and increasing patient awareness

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=909

Hospitals  accounted for the largest share 57.8% of the end user segment of the brain monitoring market.

Based on end-users, the global brain monitoring devices market is segmented into hospitals, neurology centers, diagnostic centers, ASCs & clinics, and other end users. The hospital segment held the largest share 57.8% of the global brain monitoring market in 2020. Brain monitoring is a complex process, requiring expensive and advanced devices and equipment that are mainly found in hospitals. Hospitals also see a considerably larger inflow of patients as compared to small clinics and other end users. Additionally, brain monitoring devices pose a considerable burden in terms of maintenance expenses on healthcare facilities; hospitals, more than other end-users, can bear such costs. Hence, brain monitoring devices are mostly used in hospitals, which consequently account for the largest share of this market segment.

North America accounted for the largest share 38.0% of the global brain monitoring market

North America, Europe, the Asia Pacific, and the Rest of the World. North America held the largest share 38.0% of the global brain monitoring market in 2020, while the Asia Pacific is projected to be the fastest-growing region in the forecast period. The high growth rate of the market in the Asia Pacific region can be attributed to the availability of low-cost labor and skilled manpower, increase in disposable incomes, rising prevalence of neurodegenerative disorders, and increasing government emphasis on healthcare reforms in the region.

Some of the leading players in the Brain Monitoring market include Natus Medical, Inc. (US), Nihon Kohden Corporation (Japan), Philips Healthcare (Netherlands), GE Healthcare (US), Siemens Healthineers (Germany), Compumedics, Ltd. (Australia), Medtronic (Ireland), Edwards Lifesciences Corporation (US), Drägerwerk AG & Co. KGaA (Germany), Advanced Brain Monitoring (US), Masimo Corporation (US), Spiegelberg GmbH & Co. KG (Germany), Cadwell Industries (US), NeuroWave Systems, Inc. (US), Nonin Medical, Inc. (US), Integra LifeSciences Corporation (US), Neurosoft (Russia), CGX (a Cognionics Company) (US), Emotive (US), InfraScan, Inc. (US), Neusoft Medical Systems Co., Ltd. (China), Clinical Science Systems (Netherlands), Noraxon (US), SternMed GmbH (Germany), and Rimed (US).

Speak to Analyst@
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=909

Human Microbiome Market worth $1,598 million by 2028

 Overview:

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market.

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Expected Revenue Growth:

The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.

Growth Boosting Factors:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period.

The drugs segment to account for the largest share of the product segment in the global human microbiome market  in 2024

Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. The drugs segment is expected to account for the largest share of the human microbiome market in 2024. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs.

The therapeutics segment to account for the largest share of the market in 2024

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2024. The increase in funding for R&D in microbiome-based therapies worldwide is the major factor driving the growth of this application segment. Technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes also support market growth

The infectious diseases segment to account for the largest share of the market in 2024

Based on disease, the human microbiome market is segmented into five categories—infectious diseases, metabolic disorders, gastrointestinal diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global human microbiome market in 2024. The large share of this segment can be attributed to the increasing research in microbiome-based products and their use in treating infectious diseases. The major focus is on developing products targeting the microbiome modulators for infectious diseases, which accounts for 40-50 products currently in the pipeline.

The Asia Pacific region is the fastest growing region of human microbiome research spending market in 2019

On the basis of region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2019. In 2019, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2020-2025.  Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Global Leading Companies:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).

Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026

 Overview:

Market Size Estimation

The total size of the pharmaceutical drug delivery market was arrived at after data triangulation from different approaches, as mentioned below. After each approach, the weighted average of the approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Projected Revenue Growth:

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period.

Growth Boosting Factors:

Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.

The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period

Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment accounted for the highest CAGR of the pharmaceutical drug delivery market. This can be attributed to convenience and the ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.

The infectious diseases segment is expected to account for the largest share of the pharmaceutical drug delivery market

Based on application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.

Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market

During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Global Key Players:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).

Pharmaceutical Excipients Market worth $10.6 billion by 2026

 Expected Revenue Growth:

The pharmaceutical excipients  market is projected to reach USD 10.6 billion by 2026 from USD 7.9 billion in 2021, at a CAGR of 5.8% during the forecast period.

Growth Boosting Factors:

The overall growth of the pharmaceutical excipients market is largely driven by the growing pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth for pharmaceutical excipients.

However, the increasing regulatory stringency regarding the approval of drugs and excipients along with the cost and time-intensive drug development process are expected to restrain the growth of this market during the forecast period.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=956

The organic excipients segment is expected to grow at the highest CAGR during the forecast period

Based on the products, the pharmaceutical excipients market is segmented into organic and inorganic chemicals.  Organic chemicals segment held significant share in 2021. The large share of this segment can be attributed to the use of these chemicals in a majority of pharmaceutical formulations. Moreover, rising global demand for pharmaceuticals has fueled the growth of drug production, thereby, positively influencing the segmental growth.

The oral formulations segment is expected to account for the largest share of the Pharmaceutical Excipients market

Based on formulation, the pharmaceutical excipients market is segmented into oral, topical, parenteral, and other formulations. In 2021, the oral formulations segment accounted for the largest share of the pharmaceutical excipients market, mainly because oral formulations are the most common drug delivery route.

The fillers & diluents segment is expected to have substantial market size during the forecast period.

Based on functionality, the pharmaceutical excipients market is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disintegrants, lubricants & glidants, preservatives, emulsifying agents, and other functionalities. The fillers & diluents segment accounted for the largest share of the pharmaceutical excipients market in 2020. This can be attributed to the increased use of fillers and diluents in solid oral drug development and production.

Asia Pacific is expected to account for the highest CAGR for players operating in the Pharmaceutical Excipients market

The Asia Pacific is the fastest-growing and most dynamic pharmerging market globally, poised to be the most attractive regional market due to its large base of generic drug manufacturers. Several factors, such as the growing Asian scientific base (due to the establishment of R&D centers and manufacturing facilities by major players in recent years); growth in the Asian pharmaceutical markets and pharmaceutica manufacturing capabilities; and the large patient pool are contributing to the growth of the pharmaceutical excipients market in the APAC.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=956

Key Players:

The prominent players in this market are DuPont (US), Colorcon Inc. (US), BASF SE (Germany), Evonik Industries AG (Germany), Ashland Global Holdings Inc. (US), Kerry Group plc (Ireland), Roquette Freres (France), Eastman Chemical Company (US), Air Liquide S.A. (France), and Merck KGaA (Germany).